ArticleEpidemics2021
Challenges of evaluating and modelling vaccination in emerging infectious diseases.
Article in Epidemics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants.BMC infectious diseases · 2023Pooled it
- Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Fractional caputo modeling of delayed disease dynamics: sensitivity analysis and control strategies incorporating environmental influences.Scientific reports · 2026Article
- Mathematical modelling for vaccine efficacy trials during the future epidemics of emerging respiratory infections.Human vaccines & immunotherapeutics · 2025Article
- Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.Clinical and experimental immunology · 2025Review
- Exploring antiviral strategies to combat African swine fever.FEMS microbiology reviews · 2025Review
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
- In silico design and analysis of a multiepitope vaccine against Chlamydia.Pathogens and disease · 2024Article
- Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.Vaccines · 2023Article
- Influenza Vaccine Effectiveness Against Influenza-Associated Hospitalization in Hong Kong Children Aged 9 Months to 17 Years, March-June 2023.Journal of the Pediatric Infectious Diseases Society · 2023Article
- Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2.American journal of epidemiology · 2023Observational
- Data analytics during pandemics: a transportation and location planning perspective.Annals of operations research · 2022Article
- The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks.Clinical trials (London, England) · 2022Article
- Challenges for modelling interventions for future pandemics.Epidemics · 2022Article
- Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.medRxiv : the preprint server for health sciences · 2022Article
- Quantifying protocols for safe school activities.PloS one · 2022Article
- Modeling the effects of vaccination, nucleic acid testing, and face mask wearing interventions against COVID-19 in large sports events.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
Abstract
Outbreaks of emerging pathogens pose unique methodological and practical challenges for the design, implementation, and evaluation of vaccine efficacy trials. Lessons learned from COVID-19 highlight the need for innovative and flexible study design and application to quickly identify promising candidate vaccines. Trial design strategies should be tailored to the dynamics of the specific pathogen, location of the outbreak, and vaccine prototypes, within the regional socioeconomic constraints. Mathematical and statistical models can assist investigators in designing infectious disease clinical trials. We introduce key challenges for planning, evaluating, and modelling vaccine efficacy trials for emerging pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.